vasoactive-intestinal-peptide and Periapical-Periodontitis

The aim of this study was to evaluate the effect of calcium hydroxide (Ca[OH]. A total of 60 patients were randomly divided into two groups that were to receive different medications. Pre-and post-treatment samples were collected from the interstitial fluid of periapical lesions using sterile paper points. VIP and MMP-9 levels were measured by enzyme-linked immunosorbent assay kits, and the data were statistically analyzed.. Gender and smoking habits had no effect on the pre- and post-treatment VIP and MMPs levels. Intragroup analyses revealed that in the Ca(OH). According to the results of the present study, the type of the medication affected the amount of periapical VIP and MMP-9 secretion.. VIP is a neuropeptide that promotes new bone formation. Thus, intracanal Ca(OH)

Topics: Adult; Calcium Hydroxide; Chlorhexidine; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Matrix Metalloproteinase 9; Periapical Periodontitis; Retreatment; Root Canal Irrigants; Root Canal Preparation; Vasoactive Intestinal Peptide

To use radioreceptor analysis for evaluating whether vasoactive intestinal peptide (VIP) receptors are present in chronic periapical lesions and to determine whether differences in its expression are found according to the size of the lesions.. Twelve periapical lesions were obtained from teeth diagnosed with chronic apical periodontitis and indicated for endodontic surgery; they were classified according to the size of the lesion in two groups of six samples (lesion size greater or smaller than 5 mm), and then processed and labelled with (125)I-VIP. Binding sites were identified by (125)I-VIP and standard VIP competition assays. Mann-Whitney's test was used to establish statistically significant differences in the VIP receptor expression between groups.. Vasoactive intestinal peptide receptor expression was found in all periapical lesion samples. There was a statistically significantly higher expression in periapical lesions <5 mm (P < 0.001).. Vasoactive intestinal peptide receptors were expressed in chronic periapical lesions with levels inversely proportional to lesion size.

Topics: Adult; Chronic Disease; Disease Progression; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Periapical Diseases; Periapical Periodontitis; Radiopharmaceuticals; Receptors, Vasoactive Intestinal Peptide; Vasoactive Intestinal Peptide

The purpose of this study was to investigate the effect of the disodium salt of ethylenediamine tetraacetate (EDTA), a calcium ion chelator used in the root canal therapy, on vasoactive intestinal peptide (VIP) binding to macrophage membranes (MM's). Binding assays were conducted at 15 degrees C in 0.5 ml of 50 mM Tris-HCl buffer (pH 7.5) containing 1.6% (w/v) bovine serum albumin, 1.2 mg/ml of bacitracin, and different EDTA concentrations, using 45 pM of [125I]VIP as tracer. Results showed that EDTA inhibits VIP binding to MM's in a dose-dependent manner, with an IC50 value of 5.4 mM (p < 0.01). EDTA concentrations equal or higher than 100 mM of abolished VIP-MM interaction. Taking into account that the macrophage plays an essential role in inflammatory reactions and the immune response, we conclude that the apical extrusion of EDTA during root canal therapy could modify VIP-macrophage interaction modulating the inflammatory mechanisms involved in periapical lesions.

Topics: Animals; Cell Membrane; Chelating Agents; Dose-Response Relationship, Drug; Edetic Acid; Egtazic Acid; Macrophages; Male; Neuroimmunomodulation; Periapical Periodontitis; Protein Binding; Rats; Rats, Wistar; Vasoactive Intestinal Peptide